ID   SiHa/VP16
AC   CVCL_XB80
DR   CCRID; 4201PAT-CCTCC00272
DR   Wikidata; Q98132574
RX   Patent=CN101503673B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200904.
CC   Population: Japanese.
CC   Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27676; Human papillomavirus-related cervical squamous cell carcinoma
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0032 ! SiHa
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 29-06-23; Version: 9
//
RX   Patent=CN101503673B;
RA   Liu S.-L., Wang H., Chen X.-L.;
RT   "Cervical cancer multidrug resistance cell strain established by
RT   etoposide induction.";
RL   Patent number CN101503673B, 12-Jan-2011.
//